Shionogi & Co., Ltd. has resolved to acquire a 50% stake in Shionogi-Apnimed Sleep Science, LLC held by Apnimed for 100 million USD (approx. 15.952 billion JPY), making it a consolidated subsidiary.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4507","jir_company_name":"Shionogi & Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-03-24","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/03\/4507-20260324-01.pdf","jir_short_summary":"Shionogi & Co., Ltd. has resolved to acquire a 50% stake in Shionogi-Apnimed Sleep Science, LLC held by Apnimed for 100 million USD (approx. 15.952 billion JPY), making it a consolidated subsidiary.","jir_summary":"### Overview of Subsidiarization\nAt the Board of Directors meeting held on March 23, 2026, Shionogi & Co., Ltd. resolved to consolidate Shionogi-Apnimed Sleep Science, LLC (SASS), an equity-method affiliate, as a consolidated subsidiary. SASS was established in 2023 as a joint venture equally funded by Shionogi & Co., Ltd. and Apnimed, aiming to develop treatments for sleep disorders. Shionogi will acquire Apnimed\u2019s 50% stake for 100 million USD (approx. 15.952 billion JPY) to increase its ownership to 100%. This move aims to fully leverage SASS\u2019s R&D capabilities and intellectual property and enable more rapid decision-making.\n\n### Future Outlook and Impact\nThe impact on consolidated financial results for the fiscal year ending March 2026 is expected to be minimal. SASS currently generates no revenue and is advancing the development of treatment candidates SASS-001 and SASS-002 for obstructive sleep apnea syndrome. Shionogi positions the sleep disorder area as a key focus and plans to strengthen R&D as a mid- to long-term growth driver.","jir_financial_highlights":"Acquisition Price: 100 million USD (equivalent in JPY: 15,952 million JPY) (Unknown)\nEquity Acquisition Ratio: 50.0% (100% after acquisition)\nAcquisition Date: Scheduled for April 6, 2026 (Unknown)","jir_category":"","jir_hashtags":"#Shionogi, #M&A, #ConsolidationAsSubsidiary, #SleepDisorders, #JapaneseStocks","jir_key_figures":"Acquisition Price: 100 million USD (equivalent in JPY: 15,952 million JPY)\nEquity Acquisition Ratio: 50.0% (before acquisition) \u2192 100% (after acquisition)\nAcquisition Date: Scheduled for April 6, 2026","jir_meta_title":"Shionogi to Consolidate Shionogi-Apnimed Sleep Science as Subsidiary for 100 Million USD","jir_meta_description":"Shionogi & Co., Ltd. acquires Apnimed\u2019s 50% stake for 100 million USD (approx. 15.952 billion JPY), accelerating R&D in the sleep disorder field through consolidation of Shionogi-Apnimed Sleep Science.","jir_og_title":"Shionogi Decides to Consolidate Sleep Disorder Subsidiary","jir_og_description":"Shionogi acquires interest in Shionogi-Apnimed Sleep Science to strengthen development of sleep disorder treatments.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6919,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"m_and_a_alliance","footnotes":""},"sector":[],"importance":[],"class_list":["post-35839","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n